281- Food & Drug Administration. Biosimilars: additional questions and answers regarding imple-
mentation of the biologics price competition and innovation act of 2009: guidance for indus-
tryhttp://www.fda.gov/downloads/Drugs/.../Guidances/UCM273001.pdf. - Louis E, Mary JY, Vernier-Massouille G, et al. Maintenance of remission among patients with
Crohn’s disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology.
2012;142:63–70 e5. quiz e31 - Ben-Horin S, Yavzori M, Benhar I, et al. Cross-immunogenicity: antibodies to infliximab
in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima. Gut.
2015;65(7):1132–8. - Gils A, Van Stappen T, Dreesen E, et al. Harmonization of Infliximab and Anti-Infliximab
Assays Facilitates the Comparison Between Originators and Biosimilars in Clinical Samples.
Inflamm Bowel Dis. 2016;22:969–75. - European Medicines Agency Assessment Report: Inflectra. http://www.ema.europa.
eu/docs/en_GB/documentlibrary/EPAR-_Public_assessment_report/human/002778/
WC500151490.pdf. - Tebbey PW, Varga A, Naill M, et al. Consistency of quality attributes for the glycosylated
monoclonal antibody Humira(R) (adalimumab). MAbs. 2015;7:805–11. - Schneider CK. Biosimilars in rheumatology: the wind of change. Ann Rheum Dis.
2013;72:315–8. - Food & Drug Administration. Guidance for Industry: Comparability Protocols —
Chemistry, Manufacturing, and Controls Information.http://www.fda.gov/downloads/Drugs/
GuidanceComplianceRegulatoryInformation/Guidances/ucm070545.pdf. - European Medicines Agency. Note for guidance on biotechnological/biological products sub-
ject to changes in their manufacturing process. http://www.ema.europa.eu/docs/en_GB/docu-
ment_library/Scientific_guideline/2009/09/WC500002805.pdf. - World Health Organization. Guidelines on the Use of INNs for Pharmaceutical Substances.
http://whqlibdoc.who.int/hq/1997/WHO_PHARM_S_NOM_1570.pdf. - Food & Drug Administration. Nonproprietary naming of biological products: guidance for
industry. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/
guidances/ucm459987.pdf. - National survey revals gastroenterologists’ views on biosimilar drugs. 2015.: http://www.
gastro.org/press_releases/2015/7/29/national-survey-reveals-gastroenterologists-views-on-
biosimilar-drugs. - Yu AP, Cabanilla LA, Wu EQ, et al. The costs of Crohn’s disease in the United States and other
Western countries: a systematic review. Curr Med Res Opin. 2008;24:319–28. - Cohen RD, Yu AP, Wu EQ, et al. Systematic review: the costs of ulcerative colitis in Western
countries. Aliment Pharmacol Ther. 2010;31:693–707. - Dretzke J, Edlin R, Round J, et al. A systematic review and economic evaluation of the use of
tumour necrosis factor-alpha (TNF-alpha) inhibitors, adalimumab and infliximab, for Crohn’s
disease. Health Technol Assess. 2011;15:1–244. - Marchetti M, Liberato NL. Biological therapies in Crohn’s disease: are they cost-effective?
A critical appraisal of model-based analyses. Expert Rev. Pharmacoecon Outcomes Res.
2014;14:815–24. - Blackstone EA, Joseph PF. The economics of biosimilars. Am Health Drug Benefits.
2013;6:469–78. - van der Valk ME, Mangen MJ, Leenders M, et al. Healthcare costs of inflammatory bowel
disease have shifted from hospitalisation and surgery towards anti-TNFalpha therapy: results
from the COIN study. Gut. 2014;63:72–9. - Burisch J, Vardi H, Pedersen N, et al. Costs and resource utilization for diagnosis and treatment
during the initial year in a European inflammatory bowel disease inception cohort: an ECCO-
EpiCom Study. Inflamm Bowel Dis. 2015;21:121–31. - Food & Drug Administration, Biologics price competition and innovation act.http://www.fda.
gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ucm216146.pdf.
15 Biosimilars in Inflammatory Bowel Disease 2017: State of the Science